Radiolabeled metaiodobenzylguanidine for the treatment of neuroblastoma

This publication has 104 references indexed in Scilit:

• Iodine-131-metaiodobenzylguanidine as initial induction therapy in stage 4 neuroblastoma patients over 1 year of age
  European Journal Of Cancer, 2008
• Endocrine late effects from multi-modality treatment of neuroblastoma
  European Journal Of Cancer, 2005
• A new approach in the treatment of stage IV neuroblastoma using a combination of [131I]meta-iodobenzylguanidine (MIBG) and cisplatin
  European Journal Of Cancer, 1995
• First line targeted radiotherapy, a new concept in the treatment of advanced stage neuroblastoma
  European Journal Of Cancer, 1995
• Reverse transcriptase-polymerase chain reaction (RT-PCR) analysis of monoamine transporters in neuroblastoma cell lines: Correlations to meta-iodobenzylguanidine (MIBG) uptake and tyrosine hydroxylase gene expression
  European Journal Of Cancer, 1995
• Multi-modality megatherapy with [131I]metaiodobenzylguanidine, high dose melphalan and total body irradiation with bone marrow rescue: Feasibility study of a new strategy for advanced neuroblastoma
  European Journal Of Cancer, 1995
• Meta-iodobenzylguanidine (MIBG) inhibits malate and succinate driven mitochondrial ATP synthesis in the human neuroblastoma cell line SK-N-BE(2c)
  European Journal Of Cancer, 1995
• Clinical experience with radiation enhancement by hyperbaric oxygen in children with recurrent neuroblastoma stage IV
  European Journal Of Cancer, 1995
• Enhanced tumour uptake and in vitro radiotoxicity of no-carrier-added [131i] metaiodobenzylguanidine: Implications for the targeted radiotherapy of neuroblastoma
  European Journal Of Cancer, 1995
• Association of Multiple Copies of the N-mycOncogene with Rapid Progression of Neuroblastomas
  New England Journal of Medicine, 1985